6-溴-4-氟-1H-吲唑-3-胺 | 1227912-19-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 6-溴-4-氟-1H-吲唑-3-胺
• 英文名称: 6-bromo-4-fluoro-1H-indazol-3-amine
• CAS: 1227912-19-7
• 化学式: C₇H₅BrFN₃
• 分子量: 230.039
• InChiKey: OLSISKHGQBVTEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-溴-4-氟-1H-吲唑-3-胺 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 亚膦酸 、 三乙胺 、 亚硝酸异戊酯 作用下， 以 乙醇 为溶剂， 70.0 ℃ 、344.75 kPa 条件下， 反应 16.0h， 生成 4-氟-6-吲唑羧酸甲酯
  参考文献：
  名称：

  [EN] N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
  [FR] COMPOSÉS INDAZOLE ET INDOLE N-ALKYLÉS UTILISÉS EN TANT QU'INHIBITEURS DE RORGAMMAT ET UTILISATIONS DE CEUX-CI

  摘要：

  公开号：

  WO2014028591A3
• 作为产物：
  描述：

  4-溴-2,6-二氟苯腈 在 hydrazine hydrate 作用下， 以 正丁醇 为溶剂， 反应 4.0h， 生成 6-溴-4-氟-1H-吲唑-3-胺
  参考文献：
  名称：

  1 H-吲哚-3-胺衍生物作为有效的成纤维细胞生长因子受体抑制剂的优化

  摘要：

  成纤维细胞生长因子受体（FGFR）由于其在促进癌症形成和发展中的关键作用而成为癌症治疗的潜在靶标。为了不断改善带有吲唑骨架的命中化合物7r的细胞活性（这是我们小组先前发现的），设计，合成了几种利用氟取代基的化合物，并对其进行了生物学评估。此外，还探索了向溶剂延伸至ATP结合口袋的区域。其中，含有2，6-二氟-3-甲氧基苯基残基的化合物2a表现出最强的活性（FGFR1：小于4.1nM，FGFR2：2.0±0.8nM）。更重要的是化合物2a结果显示对KG1细胞系和SNU16细胞系的抗增殖作用得到改善，IC 50值分别为25.3±4.6 nM和77.4±6.2 nM。

  DOI：

  10.1016/j.bmcl.2017.06.068

文献信息

• Oxidative Rearrangement of 3-Aminoindazoles for the Construction of 1,2,3-Benzotriazine-4(3<i>H</i>)-ones at Ambient Temperature
  作者：Yao Zhou、Ya Wang、Yixian Lou、Qiuling Song

  DOI：10.1021/acs.orglett.8b02813

  日期：2018.10.19

  A novel oxidative rearrangement of 3-aminoindazoles is reported, enabling the production of diverse functionalized 1,2,3-benzotriazine-4(3H)-ones in good yields at room temperature. The key success of this unprecedented transformation of 3-aminoindazoles is the use of water as cosolvent, which could facilitate the halogen-induced ring expansion of 3-aminoindazoles under oxidative conditions.

  报道了3-氨基吲唑的新型氧化重排，使得能够在室温下以高收率生产各种官能化的1,2,3-苯并三嗪-4（3 H）-。3-氨基吲唑这种前所未有的转化的关键成功是使用水作为助溶剂，它可以促进3-氨基吲唑在氧化条件下卤素诱导的环膨胀。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010059658A1

  公开（公告）日：2010-05-27

  The invention is directed to 6-(4-pyιϊmidinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及6-(4-吡咯嗪基)-1 H-吲唑衍生物。具体而言，该发明涉及符合式(I)的化合物，其中R1-R4在此处被定义。该发明的化合物是PDK1的抑制剂，可用于治疗由于恒定激活的ACG激酶所特征化的免疫和代谢性疾病和紊乱，如癌症，更具体地说是乳腺癌、结肠癌和肺癌。因此，该发明进一步涉及包括该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包括该发明化合物的药物组合物来抑制PDK1活性和治疗相关疾病的方法。
• N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150210687A1

  公开（公告）日：2015-07-30

  The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

  本发明涉及按照式I的化合物及其药用可接受盐或溶剂。这些化合物可用于治疗RORgammaT介导的疾病或症状。
• CHEMICAL COMPOUNDS
  申请人：Axten Jeffrey Michael

  公开号：US20110275611A1

  公开（公告）日：2011-11-10

  The invention is directed to 6-(4-pyrimidinyl)-1H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R 1 -R 4 are defined herein. The compounds of the invention axe inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention

  本发明涉及6-(4-嘧啶基)-1H-吲唑衍生物。具体而言，本发明涉及公式（I）中R1-R4所定义的化合物。本发明的化合物是PDK1的抑制剂，可用于治疗免疫和代谢性疾病和障碍，这些疾病和障碍以恒定激活的ACG激酶为特征，例如乳腺、结肠和肺癌等。因此，本发明还涉及包含本发明化合物的制药组合物。本发明还涉及使用本发明化合物或包含本发明化合物的制药组合物抑制PDK1活性和治疗相关障碍的方法。
• Chemical compounds
  申请人：Axten Jeffrey Michael

  公开号：US08697685B2

  公开（公告）日：2014-04-15

  The invention is directed to 6-(4-pyrimidinyl)-1H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1-R4 are defined herein. The compounds of the invention axe inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及6-(4-嘧啶基)-1H-吲唑衍生物。具体而言，本发明涉及公式(I)中R1-R4所定义的化合物。本发明的化合物是PDK1的抑制剂，可用于治疗免疫和代谢性疾病和障碍，这些疾病和障碍以恒定激活的ACG激酶为特征，例如乳腺癌、结肠癌和肺癌等癌症。因此，本发明进一步涉及包括本发明化合物的药物组合物。本发明还涉及使用本发明化合物或包括本发明化合物的药物组合物来抑制PDK1活性和治疗与之相关的疾病的方法。